Description
Recombinant Human LYPD3 Protein (His Tag) | PKSH030987 | Gentaur US, UK & Europe Disrtribition
Synonyms: Ly6/PLAUR Domain-Containing Protein 3; GPI-Anchored Metastasis-Associated Protein C4.4A Homolog; Matrigel-Induced Gene C4 Protein; MIG-C4; LYPD3; C4.4A
Active Protein: N/A
Activity: A DNA sequence encoding the human LYPD3 (NP_055215.2) C-terminal segment (Met 1-His 286) was expressed; with a polyhistidine tag at the C-terminus.
Protein Construction: A DNA sequence encoding the human LYPD3 (NP_055215.2) C-terminal segment (Met 1-His 286) was expressed; with a polyhistidine tag at the C-terminus.
Fusion Tag: C-His
Species: Human
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg of the protein as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 28.3 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Ly6 / PLAUR domain-containing protein 3; also known as GPI-anchored metastasis-associated protein C4.4A homolog; Matrigel-induced gene C4 protein; MIG-C4 and LYPD3; is a cell membrane protein which contains two UPAR/Ly6 domains. Human LYPD3 contains two UPAR/Ly6 domains. LYPD3 is expressed in placenta; skin and urothelium. It is found in suprabasal keratinocytes of chronic wounds. Weak expression of LYPD3 is found in esophagus and peripheral blood mononuclear cells. It is found in the majority of primary and metastatic transitional cell carcinomas (TCCs) and as well in breast cancer tissues; but not in adjacent normal tissues. High expression of LYPD3 is found in the tumor component of some noninvasive superficial lesions and in invasive and metastatic urothelial cancers. LYPD3 is up-regulated in migrating keratinocytes during epithelisation of incisional skin wounds. LYPD3 supports cell migration. It may be involved in urothelial cell-matrix interactions. It may also be involved in tumor progression
Research Area: Cancer
